We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




MALDI-TOF-MS Evaluated for Rapid Diagnosis of Bacteremia and Fungemia

By LabMedica International staff writers
Posted on 13 Jan 2021
Print article
Image: The Microflex LT MALDI-TOF mass spectrometer and Rapid Sepsityper kit for the identification of pathogenic organisms (Photo courtesy of Bruker Daltonics).
Image: The Microflex LT MALDI-TOF mass spectrometer and Rapid Sepsityper kit for the identification of pathogenic organisms (Photo courtesy of Bruker Daltonics).
When sepsis occurs, it is essential to begin an effective and potent antibacterial or antifungal treatment as soon as possible as early administration and achievement of microbicidal concentrations are associated with better survival in community-acquired and hospital-acquired septicemia.

Rapid species identification is now possible by several techniques directly from positive blood cultures. It allows a first quick adaptation of empirical treatment if inappropriate, according to the species identified. However, available techniques are either expensive such as multiplex polymerase chain reaction (PCR) or fluorescence in situ hybridization using peptide nucleic acid probes (PNA-FISH), that are delayed by a first 4 to 8 hours subculture on agar medium or are time-consuming.

Medical Microbiologists at the Université Grenoble Alpes (Grenoble, France) analyzed 379 positive blood cultures bottles and all the blood cultures were incubated in a BD BACTEC FX instrument (Becton Dickinson, Franklin Lakes, NJ, USA). Among those, 299 samples were selected as they corresponded to the first positive blood culture bottle for all new episodes of bacteremia during random days. Fifty-one positive blood cultures bottles were also included in the study in order to compare identification rates obtained on aerobic or anaerobic bottles for facultative anaerobes (27 second positive bottle of a pair of blood culture already included and 12 additional pairs of positive blood culture).

Matrix Assisted Laser Desorption Ionization—Time of Flight Mass Spectrometry (MALDI-TOF-MS) identification was performed using either the Rapid protocol (10 minutes turnaround time) of the Sepsityper kit (Bruker Daltonics, Bremen, Germany) or the Standard procedure (30 minutes turnaround time). MALDI‑TOF-MS data analysis and evaluation of performance were all acquired on a Bruker Daltonics’ Microflex LT MALDI-TOF mass spectrometer. To provide an optimized diagnosis strategy the team also evaluated the benefit of using an on-plate formic acid extraction step and compared identification rates depending on the type of positive blood culture bottles (aerobic or anaerobic) for facultative anaerobes.

The investigators reported that identification rates were determined prospectively on 350 bacterial and 29 fungal positive blood cultures, and compared to conventional diagnostic method. Their rapid diagnosis strategy (Rapid Sepsityper protocol: one spot with and one without formic acid extraction step) combined to MBT-Sepsityper module provided 65.4%, 78.9% and 62% reliable identification to the species level of monomicrobial positive blood cultures growing respectively Gram-positive, Gram-negative bacteria or yeast.

Importantly, identification rates of Gram-positive bacteria were higher in anaerobic than in aerobic bottles (77.8% versus 22.2%), if formic acid extraction step was performed (60.8% versus 39.2%) and if specific MBT-Sepsityper module was used (76.2% versus 61.9%), while no significant differences were observed for Gram-negative bacteria. For yeasts identification, formic acid extraction step improved rapid identification rate by 37.9% while the specific MBT-Sepsityper module increased overall performances by 38%, providing up to 89.7% reliable identification if associated with the standard Sepsityper protocol.

The authors concluded that the rapid Sepsityper protocol is an interesting commercial assay for quick bacterial identification in bloodstream infections (BSI) that could allow early adaptation of empirical antibiotic treatment according to the species identified. The study was published on December 9, 2020 in the journal Annals of Clinical Microbiology and Antimicrobials.

Related Links:
Université Grenoble Alpes
Becton Dickinson
Bruker Daltonics



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.